

Dear Trading Partner,

Please see the attached eligibility file which is effective 6/23/2025 with the exception of Vermont which is retroactively effective 6/11/23 per the attached files.

IMPORTANT! New Updates:

Effective June 11, 2025, contract pharmacy arrangements between 340B covered entities located in **Vermont** and their contract pharmacies are fully exempted* from Merck's 340B Program Integrity Initiative

Effective July 1, 2025, contract pharmacy arrangements between 340B covered entities located in **Tennessee** and their contract pharmacies are fully exempted* from Merck's 340B Program Integrity Initiative.

Effective July 1, 2025, contract pharmacy arrangements between 340B covered entities located in **Hawaii** and their contract pharmacies are partially exempted* from Merck's 340B Program Integrity Initiative.

Effective August 6, 2025, contract pharmacy arrangements between 340B covered entities located in **Colorado** and their contract pharmacies are fully exempted* from Merck's 340B Program Integrity Initiative.

***Merck Policy Definitions: Merck 340B Program Integrity Initiative**

Merck's National Policy*: one contract pharmacy, data required.

Merck's Partially Exempted* State Policy: unlimited contract pharmacies, data required.

Merck's Fully Exempted* State Policy: unlimited contract pharmacies, data **NOT** required.

The updated 340b policy has been communicated to our vendor, 340B ESP, and will be posted on their website and communicated to customers in the impacted states.

+++++

Effective March 31, 2025, Merck will implement the following eligibility changes to its contract pharmacy policy under the Merck 340B Program Integrity Initiative:

- Merck will begin requiring submissions of 340B claims data for claims originating from eligible contract pharmacies as noted in Merck’s 340B Program Integrity Initiative.
- The claims noted above must be submitted through Merck’s vendor, Second Sight Solutions, through their 340B ESP platform.
- An updated policy notification was sent to all covered entities on March 20, 2025. Please refer to this Merck policy notification for all new updates effective March 31, 2025 as posted in Resources on Second Sight Solution’s web site (www.340BESP.com).

Effective April 9, 2025, contract pharmacy arrangements between 340B covered entities located in **Nebraska** and their contract pharmacies are fully exempted* from Merck’s 340B Program Integrity Initiative.

Effective May 7, 2025, contract pharmacy arrangements between 340B covered entities located in **Utah** and their contract pharmacies are fully exempted* from Merck’s 340B Program Integrity Initiative.

Effective July 1, 2025, contract pharmacy arrangements between 340B covered entities located in **South Dakota** and their contract pharmacies are fully exempted* from Merck’s 340B Program Integrity Initiative. Prior to July 1, 2025, 340B covered entities located in South Dakota shall be subject to Merck’s 340B Program Integrity Initiative.

Effective August 1, 2025, contract pharmacy arrangements between 340B covered entities located in **North Dakota** and their contract pharmacies are fully exempt* from Merck’s 340B Program Integrity Initiative.

+++++

- **Eligibility Rules:** Please refer to Merck policy via Merck’s vendor Second Sight Solutions (www.340BESP.com).
- Applicable Hospital and Consolidated Health Center Program (CH /CHC) covered entities (*Merck’s policy only applies to Hospital and CH/CHC*)
 - **CH/CHC** Consolidated Health Center Program (CH / CHC)
 - **DSH** Disproportionate Share Hospital (DSH)
 - **CAH** Critical Access Hospital (CAH)
 - **SCH** Sole Community Hospital (SCH)
 - **RRC** Rural Referral Center (RRC)
 - **PED** Children's Hospital
 - **CAN** Free Standing Cancer Hospital (CAN)
- **Except for CH/CHC, federal grantee covered entities** continue to be **exempt** from this policy including:
 - **STD** Sexually Transmitted Diseases
 - **FP** Family Planning – Title X (FP) (includes only Title X funded)
 - **RWI** Ryan White Part A (formerly Title I)
 - **HV** Ryan White Part C (formerly Title III)
 - **RWII** Ryan White Part B (formerly Title II)
 - **RWIID** Ryan White Part B (formerly Title II) ADAP Direct Purchase

- **TB** Tuberculosis
- **UI** Urban Indian (UI) Health Center
- **BL** Black Lung Clinics Program
- **HM** Comprehensive Hemophilia Treatment Center (HTC)
- **NH** Native Hawaiian Health Care Program

- **Products:** Only NDC's in these **8 product families** remain **in scope**

Table 1. Applicable Merck covered outpatient drug products	
1.	BELSOMRA® (suvorexant)
2.	JANUVIA® (sitagliptin)
3.	JANUMET® (sitagliptin and metformin hydrochloride)
4.	JANUMET® XR (sitagliptin and metformin hydrochloride extended release)
5.	STEGLATRO® (ertugliflozin)
6.	STEGLUJAN® (ertugliflozin and sitagliptin)
7.	SEGLUROMET® (ertugliflozin and metformin)
8.	VERQUVOTM (vericiguat)

- Covered entity's that have questions can be directed to contact Second Sight Solutions at www.340BESP.com.

If you have any questions or need additional information, please let us know.

Thank you,

Merck CCS Distributor Segment Team